Singapore: US-based Avantor Performance Materials has introduced a higher purity Super Refined grade of polysorbate prod...
Singapore: Novartis Foundation for Sustainable Development (NFSD) has launched a new leprosy strategy focused on interru...
Singapore: AstraZeneca and NN Petrov Institute of Oncology, one of Russia's leading cancer research institutions, signed...
Singapore: A rapid heart rate is a common condition among elderly individuals, and represents a potential goldmine for p...
Singapore: Experimental Therapeutics Center (ETC) and Exploit Technologies of Agency for Science, Technology and Researc...
Singapore: The US Food and Drug Administration (FDA) has approved Stribild, a complete once-daily single tablet regimen ...
Singapore: Bionomics is going to present clinical trial data from its ongoing US trial of BNC105 in patients with metast...
Singapore: QRxPharma received complete response letter (CRL) regarding the company's Moxduo new drug application (NDA) f...
Singapore: 3SBio, China based biotechnology company, has signed license agreement with JenKem Technology to develop, man...
Singapore: Japanese firm Takeda Pharmaceutical has formed a research collaboration with the BC Cancer Agency to explore ...
Singapore: With the strategy to strengthen its pain management portfolio, global biopharmaceutical company, Teva Pharmac...
Singapore: The Japanese government has plans to help private-sector companies in exporting as early as 2015 regenerative...
Bayer HealthCare received approval in Japan for Gadovist (gadobutrol) injection for use with magnetic resonance imaging ...
Singapore: Australia-based GI Dynamics has conducted a new meta-analysis that demonstrates EndoBarrier Therapy, an endos...
Singapore: Data from the once-daily chronic obstructive pulmonary disease (COPD) clinical trial programs were presented ...
Singapore: The Korea Drug Development Fund (KDDF) has chosen PAREXEL International, a leading global biopharmaceutical s...
Singapore: Non-small cell lung cancer (NSCLC) therapeutics market value in the Asia-Pacific (APAC) region, Australia, Ch...
Singapore: Glaxosmithkline declared that the phase III study of two anti-HER2 agents lapatinib and trastuzumab did not m...
